Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Matthew Snape, Professor of Paediatrics and Vaccinology at the Oxford Vaccine Group (OVG) before moving to Moderna in August 2022, has been appointed Member of the Most Excellent Order of the British Empire (MBE) for services to Public Health, particularly during COVID-19 while working at the OVG.

He said: ‘This is a such a wonderful honour, and I am delighted to receive this recognition. It is especially rewarding that this emphasises the importance of Public Health given the vital role that immunisation has in maintaining the health of the population. This work was only possible due to the wonderful team at the Oxford Vaccine Group, and my gratitude to my colleagues and friends there is profound and heartfelt.'

Read more here: New Year Honours 2024 | University of Oxford

Similar stories

A New Era for Childhood Cancer Research: Professor Isidro Cortés Ciriano Appointed as Oxford's First Little Princess Trust Professor of Paediatric Oncology

The Department of Paediatrics at the University of Oxford has appointed Professor Isidro Cortés-Ciriano as its first Little Princess Trust Professor of Paediatric Oncology, marking a major milestone in a partnership dedicated to accelerating the development of new treatments for children with cancer.

Oxford University and King’s College London Join IMPACT Network Study to Advance Understanding of Profound Autism

The University of Oxford and King’s College London (King’s) have joined the Innovative Medicine and Precision Approaches to Clinical Trials (IMPACT) Network, an international collaboration of sites working together to accelerate clinical trial readiness and therapeutic development for autism through a large-scale natural history and clinical endpoint study.

Scientists in the Department of Paediatrics discover antibody combinations that block over 90% of malaria parasite growth

In an important discovery for the next-generation of malaria vaccines, University of Oxford researchers in the Department of Paediatrics, in collaboration with the Scripps Institute, have identified how antibodies can be over 90% effective at preventing malaria parasites from growing in certain combinations.

Statement on vaccine efforts relating to the Bundibugyo Ebolavirus outbreak in the DRC

In response to the current Bundibugyo Ebolavirus outbreak in the Democratic Republic of the Congo, the Oxford Vaccine Group (OVG) is working urgently with Oxford’s own Clinical BioManufacturing Facility and the Serum Institute of India Pvt. Ltd. (SIIPL), to rapidly produce and scale doses of our ChAdOx-based monovalent Bundibugyo Ebolavirus candidate vaccine, ChAdOx1 BDBV.

University of Oxford and Serum Institute of India Agree Licence to Advance the Next-Generation Multi-Stage Malaria Vaccine Candidate Component R78C

The University of Oxford, through Oxford University Innovation (OUI), and the Serum Institute of India (SII), a Cyrus Poonawalla group company and the world’s largest vaccine manufacturer by volume, have entered into a licence agreement to support the development and manufacture of the new malaria vaccine candidate R78C, which has been developed by the Draper Lab in the Department of Paediatrics, and is based on two Plasmodium falciparum blood-stage antigens (RIPR and CyPRA), for use in clinical settings.

Major technological advance reveals how mutations in a tiny non-coding gene cause multiple neuro-developmental disorders

Researchers from the University of Oxford and the Francis Crick Institute, in collaboration with international partners, have made major advances in understanding how mutations in a single non-coding gene contribute to neurodevelopmental disorders affecting thousands of people worldwide.